6533b7d5fe1ef96bd1264994

RESEARCH PRODUCT

Steroid and vasoactive treatment for acute deafness after attempted hearing preservation acoustic neuroma surgery.

Jan MaurerTorsten MewesWolf J. MannHaralampos Gouveris

subject

medicine.medical_specialtymedicine.drug_classHearing lossmedicine.medical_treatmentPrednisoloneVasodilator AgentsAnti-Inflammatory AgentsAcoustic neuromaDeafnessHydroxyethyl Starch DerivativesPostoperative ComplicationsAcoustic neuroma surgeryVasoactiveotorhinolaryngologic diseasesmedicineEvoked Potentials Auditory Brain StemHumansIn patientPentoxifyllineRetrospective StudiesSalvage TherapyHearing preservationChemotherapybusiness.industryNeuroma Acousticmedicine.diseaseSurgeryOtorhinolaryngologyAnesthesiaAcute DiseaseInjections IntravenousCorticosteroidDrug Therapy Combinationmedicine.symptombusiness

description

<i>Objective:</i> To investigate whether intravenous steroid and vasoactive therapy in the acute postoperative period improves hearing outcome in patients who develop acute deafness after attempted hearing preservation surgery for acoustic neuroma (AN) through a retrosigmoid or a middle cranial fossa approach. <i>Study Design and Setting:</i> Retrospective controlled study in a tertiary care center. Thirty-six patients who had developed acute deafness after hearing preservation surgery for treatment of an AN were reviewed. Preoperative AAOHNS hearing class was A in 2, B in 2 and D in 32 patients. Twenty-seven patients were treated with prednisolone, hydroxyethyl starch 3% and pentoxifylline intravenously for a period of at least 5 days. Nine patients (controls) did not receive any specific steroid or vasoactive therapy. <i>Results:</i> All patients in both groups remained deaf. <i>Conclusions:</i> Intravenous therapy with prednisolone, hydroxyethyl starch 3% and pentoxifylline in the acute postoperative period does not improve hearing in patients who develop acute deafness after attempted hearing preservation surgery for AN.

10.1159/000084296https://pubmed.ncbi.nlm.nih.gov/15753619